SEC Form 4 · accession 0001193125-26-274224
CORCEPT THERAPEUTICS INC · CORT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Atabak Mokari
Officer — Chief Financial Officer
Period of report
Jun 15, 2026
Accepted (ET)
Jun 17, 2026 · 4:30 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001088856
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 15, 2026 | M | 40,000 | $19.26 | A | 56,130 | D | |
| Common StockF3,F1 | Jun 15, 2026 | S | 9,434 | $80.0216 | D | 46,696 | D | |
| Common StockF4,F1 | Jun 15, 2026 | S | 11,081 | $80.9424 | D | 35,615 | D | |
| Common StockF5,F1 | Jun 15, 2026 | S | 19,483 | $81.8092 | D | 16,132 | D | |
| Common StockF1 | Jun 15, 2026 | S | 2 | $82.45 | D | 16,130 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F6 | $19.26 | Jun 15, 2026 | M | 40,000 | D | — | Feb 2, 2032 | Common Stock | 40,000 | 20,000 | D |
Explanation of responses
- F1Includes 200 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 397 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
- F2This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 12, 2025 in effect at the time of this transaction.
- F3Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $79.40 to $80.39 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- F4Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $80.40 to $81.39 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- F5Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $81.40 to $82.18 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- F6Fully exercisable.
Remarks
The power of attorney under which this form was signed is on file with the Commission.